United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

After a 63% rise since the March 23 levels of this year, at the current price of around $137 per share we believe United Therapeutics stock (NASDAQ: UTHR), a biotechnology company, has reached its near-term potential.

United Therapeutics Stock Looks Fully Valued At $137

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients with...

United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

United Therapeutics (UTHR) Up 2.3% Since Last Earnings Report: Can It Continue?

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's...

United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference

United Continental Hlds

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q3 2020 Results - Earnings Call Transcript

Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 1.31% over the past year to $3.88, which beat the estimate of $2.78.

Recap: United Therapeutics Q3 Earnings

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, 2020. "As our core business continues to perform well, we have a solid footing to...

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of nearly 823 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has the potential to beat the market over the long-term. Therefore, let's take a closer look at what smart money thinks about United Therapeutics Corporation (NASDAQ:UTHR).

Was The Smart Money Right About United Therapeutics Corporation (UTHR)?

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced new clinical data on Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung...

United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 financial results before the market opens on Wednesday, October 28, 2020. United Therapeutics will...

United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020

Alexion Pharma

Amgen

BioMarin Pharmaceutical

Insmed

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

7 Large Biotechs Expected to Outperform This Earnings Season

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present clinical trial data on Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with...

United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a...

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors

United Therapeutics (UTHR) Down 6.9% Since Last Earnings Report: Can It Rebound?

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

Allogene Therapeutics Inc

DraftKings

MyoKardia

Plug Power

Acceleron Pharma

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

7 Best Stocks to Buy Now for More Red-Hot Returns

United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease

United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q2 2020 Results - Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of 0.00% and 6.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q2 Earnings Meet Estimates

Shares of United Therapeutics (NASDAQ:UTHR) were unchanged after the company reported Q2 results.

News for United Therapeutics Stock (UTHR)